HRP20230747T1 - Neuroaktivni steroidi, pripravci i njihova uporaba - Google Patents
Neuroaktivni steroidi, pripravci i njihova uporaba Download PDFInfo
- Publication number
- HRP20230747T1 HRP20230747T1 HRP20230747TT HRP20230747T HRP20230747T1 HR P20230747 T1 HRP20230747 T1 HR P20230747T1 HR P20230747T T HRP20230747T T HR P20230747TT HR P20230747 T HRP20230747 T HR P20230747T HR P20230747 T1 HRP20230747 T1 HR P20230747T1
- Authority
- HR
- Croatia
- Prior art keywords
- image
- substituted
- compound
- unsubstituted
- group
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 150000003431 steroids Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 26
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- 239000001257 hydrogen Substances 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 5
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 230000009529 traumatic brain injury Effects 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000004474 heteroalkylene group Chemical group 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 125000004450 alkenylene group Chemical group 0.000 claims 2
- 125000004419 alkynylene group Chemical group 0.000 claims 2
- 208000029560 autism spectrum disease Diseases 0.000 claims 2
- 125000002837 carbocyclic group Chemical group 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 208000009205 Tinnitus Diseases 0.000 claims 1
- 206010048010 Withdrawal syndrome Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000024732 dysthymic disease Diseases 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229940127240 opiate Drugs 0.000 claims 1
- 208000022821 personality disease Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000022610 schizoaffective disease Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 231100000886 tinnitus Toxicity 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
- C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C07J1/0029—Ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/003—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring the S atom directly linked to a ring carbon atom of the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
- C07J41/0011—Unsubstituted amino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
- C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J75/00—Processes for the preparation of steroids in general
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Claims (22)
1. Spoj formule (I-a1):
[image]
ili njegova farmaceutski prihvatljiva sol;
gdje:
Z je grupa formule (iv), ili (v):
[image]
ili
[image]
Y je -O-;
L3 je supstituirani ili nesupstituirani C1-C6 alkilen, ili supstituirani ili nesupstituirani hetero C1-C6 alkilen;
R3b je vodik;
R3a je supstituirana ili nesupstituirana C1-C6 alkil;
svaka instanca R2, R11a, i R11b je neovisno vodik ili -ORB1, pri čemu RB1 je vodik ili supstituirani ili nesupstituirani alkil, ili R11a i R11b su spojeni da formiraju okso (=O) grupu;
R6a je vodik, halo ili supstituirani ili nesupstituirani C1-C6 alkil;
svaka instanca RZ5 je neovisno vodik ili supstituirani ili nesupstituirani alkil; i
svaka instanca RZ6 je neovisno vodik ili supstituirani ili nesupstituirani alkil, ili dvije RZ6 grupe su spojene da formiraju C3-6 karbociklični prsten.
2. Spoj prema patentnom zahtjevu 1 naznačen time što je Z grupa formule:
[image]
3. Spoj prema patentnom zahtjevu 2, naznačen time što L3 je grupa formule:
[image]
pri čemu p je 1, 2 ili 3; i svaka instanca RZ7 i RZ8 je, neovisno, vodik, halo, supstituirani ili nesupstituirani C1-6 alkil, ili -ORZ5.
4. Spoj prema patentnom zahtjevu 2, naznačen time što L3 je grupa formule:
[image]
[image]
[image]
ili
[image]
5. Spoj prema patentnom zahtjevu 2, naznačen time što Y je -O- i L3 je C1-C6 alkilen ili C1-C6 heteroalkilenska grupa.
6. Spoj prema patentnom zahtjevu 5, naznačen time što grupa
[image]
je formule:
[image]
[image]
[image]
[image]
[image]
ili
[image]
7. Spoj prema patentnom zahtjevu 1, naznačen time što je Z grupa formule:
[image]
8. Spoj prema patentnom zahtjevu 7, naznačen time što Y je -O- i L3 je C1-C6 alkilen ili C1-C6 heteroalkilen grupa.
9. Spoj prema patentnom zahtjevu 8, naznačen time što grupa
[image]
je formule:
[image]
[image]
ili
[image]
10. Spoj prema patentnom zahtjevu 1, naznačen time što R11b je vodik ili -ORB1, i R11a je vodik.
11. Spoj formule (I-e):
[image]
ili njegova farmaceutski prihvatljiva sol;
gdje:
L3 je supstituiran ili nesupstituiran C1-C6 alkilen, supstituirani ili nesupstituirani C2-C6 alkenilen, supstituirani ili nesupstituirani C2-C6 alkinilen, supstituirani ili nesupstituirani hetero C1-C6 alkilen, supstituirani ili nesupstituirani hetero C2-C6 alkenilen, ili supstituirani ili nesupstituirani hetero C2-C6 alkinilen;
R3a je supstituiran ili nesupstituiran C1-C6 alkil;
svaka instanca R2, R11a, i R11b je neovisno vodik ili -ORB1, pri čemu
pri čemu RB1 je vodik ili supstituirani ili nesupstituirani alkil, ili R11a i R11b su spojeni da formiraju okso (=O) grupu;
svaki od R6a i R6b je neovisno vodik, halo, ili supstituirani ili nesupstituirani C1-C6 alkil, i - - - - - - predstavlja jednostruku ili dvostruku vezu, pod uvjetom da je prisutna dvostruka veza, onda jedan od R6a ili R6b je odsutan, a pod uvjetom da je prisutna jednostruka veza, onda je vodik na C5 u alfa ili beta položaju;
R19 je vodik ili -CH3; i
svaka instanca RZ6 je neovisno vodik ili supstituirani ili nesupstituirani alkil, ili dve RZ6 grupe se udružuju da formiraju C3-6 karbociklični prsten.
12. Spoj prema patentnom zahtjevu 11, naznačen time što L3 je C1-C6 alkilen ili heteroalkilen grupa.
13. Spoj prema patentnom zahtjevu 11, naznačen time što - - - - - - predstavlja dvostruku vezu.
14. Spoj prema patentnom zahtjevu 11, naznačen time što R19 je -CH3.
15. Spoj prema patentnom zahtjevu 1, naznačen time što je spoj izabran iz grupe koja se sastoji od:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
ili njegova farmaceutski prihvatljiva sol.
16. Spoj, naznačen time što je spoj izabran iz grupe koja se sastoji od:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
ili njegova farmaceutski prihvatljiva sol.
17. Spoj, naznačen time što je spoj izabran iz grupe koja se sastoji od:
[image]
[image]
ili njegova farmaceutski prihvatljiva sol.
18. Spoj, naznačen time što je spoj izabran iz grupe koja se sastoji od:
[image]
[image]
ili njegova farmaceutski prihvatljiva sol.
19. Farmaceutski pripravak koji sadrži farmaceutski prihvatljiv nosač i efikasnu količinu spoja, ili njegove farmaceutski prihvatljive soli, prema bilo kojem od prethodnih patentnih zahtjeva.
20. Profilaktički ili terapeutski efikasna količina spoja, ili njegove farmaceutski prihvatljive soli, ili farmaceutskog pripravka prema bilo kojem od prethodnih patentnih zahtjeva za uporabu u postupku za prevenciju, liječenje, poboljšanje ili kontrolu bolesti ili stanja.
21. Spoj, ili njegova farmaceutski prihvatljiva sol, ili farmaceutski pripravak za uporabu prema patentnom zahtjevu 20, naznačen time što je bolest ili stanje shizofrenija, depresija, bipolarni poremećaj (I i II), shizoafektivni poremećaj, poremećaji raspoloženja, poremećaji anksioznosti, poremećaji ličnosti, psihoza, kompulzivni poremećaji, posttraumatski stresni poremećaj (PTSP), poremećaj autističnog spektra (ASD), distimija (blaga depresija), socijalni anksiozni poremećaj, opsesivno kompulzivni poremećaj (OCD), svi sindromi i poremećaji bola, poremećaji spavanja, poremećaji pamćenja i demencija uključujući Alzheimerovu bolest, epilepsiju i bilo kakve poremećaje sa konvulzijama, traumatsku povredu mozga (TBI), moždani udar, poremećaje ovisnosti uključujući opijate i kokain i alkohol, autizam, Hantingtonovu bolest, nesanicu, Parkinsonovu bolest, sindrome ustezanja ili tinitus.
22. Spoj, ili njegova farmaceutski prihvatljiva sol, ili farmaceutski pripravak za uporabu prema patentnom zahtjevu 21, naznačen time što bolest ili stanje je shizofrenija, pri čemu bolest ili stanje je traumatska povreda mozga (TBI), ili pri čemu bolest ili stanje je moždani udar.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161532427P | 2011-09-08 | 2011-09-08 | |
PCT/US2012/054261 WO2013036835A1 (en) | 2011-09-08 | 2012-09-07 | Neuroactive steroids, compositions, and uses thereof |
EP12766766.5A EP2753632B1 (en) | 2011-09-08 | 2012-09-07 | Neuroactive steroids, compositions, and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20230747T1 true HRP20230747T1 (hr) | 2024-01-05 |
Family
ID=46964032
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20230747TT HRP20230747T1 (hr) | 2011-09-08 | 2012-09-07 | Neuroaktivni steroidi, pripravci i njihova uporaba |
Country Status (20)
Country | Link |
---|---|
US (4) | US20150158903A1 (hr) |
EP (2) | EP4245369A3 (hr) |
JP (5) | JP6205362B2 (hr) |
CN (3) | CN107936076B (hr) |
AU (5) | AU2012304412A1 (hr) |
BR (1) | BR112014005373B1 (hr) |
CA (1) | CA2848212C (hr) |
DK (1) | DK2753632T3 (hr) |
ES (1) | ES2951664T3 (hr) |
FI (1) | FI2753632T3 (hr) |
HK (1) | HK1200173A1 (hr) |
HR (1) | HRP20230747T1 (hr) |
HU (1) | HUE062616T2 (hr) |
LT (1) | LT2753632T (hr) |
PL (1) | PL2753632T3 (hr) |
PT (1) | PT2753632T (hr) |
RS (1) | RS64332B1 (hr) |
RU (1) | RU2665571C2 (hr) |
SI (1) | SI2753632T1 (hr) |
WO (1) | WO2013036835A1 (hr) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006047022A1 (en) | 2004-10-25 | 2006-05-04 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis |
ES2812250T3 (es) | 2005-11-28 | 2021-03-16 | Marinus Pharmaceuticals Inc | Formulaciones de ganaxolona y procedimientos para la preparación y uso de las mismas |
US9034859B2 (en) | 2011-04-06 | 2015-05-19 | Virginia Commonwealth University | Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation |
US20150158903A1 (en) | 2011-09-08 | 2015-06-11 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
WO2013043985A1 (en) | 2011-09-23 | 2013-03-28 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
CN108976272B (zh) | 2011-10-14 | 2021-05-25 | 萨奇治疗股份有限公司 | 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途 |
US20150018327A1 (en) | 2012-01-23 | 2015-01-15 | Sage Therapeutics, Inc. | Neuroactive steroid formulations and methods of treating cns disorders |
WO2014028398A2 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
EP2925327B1 (en) | 2012-11-30 | 2024-01-10 | The Regents of The University of California | Allopregnanolone for treating, reducing or mitigating symptoms of post-partum depression |
EP3865135A3 (en) * | 2013-03-13 | 2021-11-03 | Sage Therapeutics, Inc. | Neuroactive steroids for use in therapy |
BR112015022174B1 (pt) * | 2013-03-13 | 2022-07-05 | Sage Therapeutics, Inc | Compostos esteróides neuroativos, sua composição farmacêutica e seu uso |
DK2986624T3 (da) | 2013-04-17 | 2020-06-29 | Sage Therapeutics Inc | Neuroaktive 19-nor-steroider til terapeutisk anvendelse |
US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
LT2986623T (lt) * | 2013-04-17 | 2019-02-25 | Sage Therapeutics, Inc. | 19-nor c3,3-dipakeistieji c21-n-pirazolilo steroidai ir jų panaudojimo būdai |
CN103333216A (zh) * | 2013-06-04 | 2013-10-02 | 苏州大学 | 5α-6-酮-胆甾烷类似物及其应用 |
CN105555277B (zh) | 2013-07-19 | 2022-01-11 | 萨奇治疗股份有限公司 | 神经活性类固醇化合物、组合物及其用途 |
CN105579043B (zh) | 2013-08-23 | 2021-09-14 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物和其用途 |
TWI734665B (zh) | 2013-12-24 | 2021-08-01 | 維吉尼亞聯邦大學 | 氧化膽固醇硫酸鹽(ocs)之用途 |
EP4306114A1 (en) * | 2014-06-18 | 2024-01-17 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
SG10202011773UA (en) * | 2014-10-07 | 2021-01-28 | Sage Therapeutics Inc | Neuroactive compounds and methods of use thereof |
LT3206493T (lt) | 2014-10-16 | 2020-08-25 | Sage Therapeutics, Inc. | Kompozicijos ir būdai, skirti cns sutrikimams gydyti |
TW202235090A (zh) | 2014-10-16 | 2022-09-16 | 美商賽吉醫療公司 | 用於治療中樞神經系統(cns)病症之組合物及方法 |
SI3224269T1 (sl) | 2014-11-27 | 2020-10-30 | Sage Therapeutics, Inc. | Sestavki in metode za zdravljenje CNS motenj |
ES2857082T3 (es) | 2015-01-26 | 2021-09-28 | Sage Therapeutics Inc | Composiciones y métodos para el tratamiento de trastornos del SNC |
US10329320B2 (en) | 2015-02-20 | 2019-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
DK3319611T3 (da) * | 2015-07-06 | 2021-04-12 | Sage Therapeutics Inc | Oxysteroler og fremgangsmåder til anvendelse deraf |
DK3319612T3 (da) * | 2015-07-06 | 2021-08-23 | Sage Therapeutics Inc | Oxysteroler og fremgansmåder til anvendelse derfor |
EP4316591A3 (en) | 2015-07-06 | 2024-04-24 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
BR112018001869A2 (pt) * | 2015-07-30 | 2018-09-18 | Intercept Pharmaceuticals Inc | método para preparação de ácidos biliares e derivados dos mesmos |
SI3350157T1 (sl) | 2015-09-17 | 2022-04-29 | Modernatx, Inc. | Sestave za doziranje terapevtskih sredstev v celice |
CA3001722A1 (en) | 2015-10-16 | 2017-04-20 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
US9637514B1 (en) | 2015-10-26 | 2017-05-02 | MAX BioPharma, Inc. | Oxysterols and hedgehog signaling |
HUE057877T2 (hu) | 2015-12-22 | 2022-06-28 | Modernatx Inc | Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására |
JP2019508424A (ja) * | 2016-03-02 | 2019-03-28 | パセオン オーストリア ゲーエムベーハー ウント ツェーオー カーゲー | 17(20)−エン b−セコステロイドの生産のためのプロセスと中間体 |
IL300422A (en) | 2016-03-08 | 2023-04-01 | Sage Therapeutics Inc | Neuroactive steroids, preparations and their uses |
RU2754130C2 (ru) | 2016-04-01 | 2021-08-27 | Сейдж Терапьютикс, Инк. | Оксистеролы и способы их применения |
WO2017193046A1 (en) * | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
HUE055263T2 (hu) | 2016-07-07 | 2021-11-29 | Sage Therapeutics Inc | 11-Szubsztituált 24-hidroxiszterolok NMDA-hoz kapcsolódó állapotok kezelésére |
CN116162121A (zh) | 2016-07-11 | 2023-05-26 | 萨奇治疗股份有限公司 | C17、c20和c21取代的神经活性类固醇及其使用方法 |
AU2017296295B2 (en) | 2016-07-11 | 2022-02-24 | Sage Therapeutics, Inc. | C7, C12, and C16 substituted neuroactive steroids and their methods of use |
AU2017305239C1 (en) | 2016-08-02 | 2022-08-18 | Durect Corporation | Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide |
EP3481387A4 (en) | 2016-08-11 | 2020-04-08 | Ovid Therapeutics Inc | METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES |
US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
MX2019003724A (es) * | 2016-09-30 | 2019-09-04 | Sage Therapeutics Inc | Oxisteroles sustituidos en c7 y metodos de uso de los mismos. |
CN114891056A (zh) * | 2016-10-18 | 2022-08-12 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
DK3529257T3 (da) * | 2016-10-18 | 2023-08-07 | Sage Therapeutics Inc | Oxysteroler og fremgangsmåder til anvendelse deraf |
EP3538067A1 (en) | 2016-11-08 | 2019-09-18 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
RS63953B1 (sr) | 2017-03-15 | 2023-02-28 | Modernatx Inc | Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava |
WO2018170322A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Crystal forms of amino lipids |
CA3055653A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Lipid nanoparticle formulation |
CN109280069B (zh) * | 2017-07-19 | 2020-09-04 | 青岛海洋生物医药研究院股份有限公司 | 3β-羟基-麦角甾-5-烯甾类衍生物及其药物用途 |
WO2019025250A1 (en) | 2017-08-04 | 2019-02-07 | Basf Se | SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI |
IT201700100483A1 (it) * | 2017-09-07 | 2019-03-07 | Dipharma Francis Srl | Ossidazione selettiva dell’acido iodesossicolico |
EP3829589A4 (en) * | 2018-07-31 | 2022-07-27 | The Research Foundation for the State University of New York | METHOD OF ACTIVATING MICROGLIACELLS |
US20220402965A1 (en) * | 2018-09-19 | 2022-12-22 | Modernatx, Inc. | Sterol analogs and uses thereof |
WO2020118142A1 (en) | 2018-12-07 | 2020-06-11 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of pospartum depression |
CN111410678B (zh) | 2019-01-08 | 2023-02-28 | 成都康弘药业集团股份有限公司 | 甾体类化合物、用途及其制备方法 |
AR119047A1 (es) | 2019-05-31 | 2021-11-17 | Sage Therapeutics Inc | Esteroides neuroactivos como moduladores de gabaa y su uso en el tratamiento de trastornos del snc |
EP4009982A4 (en) | 2019-08-05 | 2023-08-09 | Marinus Pharmaceuticals, Inc. | GANAXOLONE FOR USE IN THE TREATMENT OF STATUS EPILEPTICUS |
TW202124360A (zh) | 2019-09-19 | 2021-07-01 | 美商現代公司 | 用於治療劑之細胞內遞送之支鏈尾端脂質化合物及組合物 |
US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
IL293525A (en) | 2019-12-06 | 2022-08-01 | Marinus Pharmaceuticals Inc | Ganaxolone for use in the treatment of multiple sclerosis complex |
CN113387991B (zh) * | 2020-03-13 | 2024-06-18 | 苏州朗科生物技术股份有限公司 | 一种合成地屈孕酮的方法及化合物 |
CZ309819B6 (cs) * | 2020-10-23 | 2023-11-08 | Univerzita Palackého v Olomouci | Sterolové deriváty, přípravky obsahující tyto deriváty a jejich použití |
CN112679571A (zh) * | 2020-12-24 | 2021-04-20 | 广西壮族自治区中国科学院广西植物研究所 | 一种罗汉果醇衍生物单体、其制备方法及应用 |
JP2024520805A (ja) | 2021-06-11 | 2024-05-24 | セージ セラピューティクス, インコーポレイテッド | アルツハイマー病の治療のための神経活性ステロイド |
WO2023049295A1 (en) | 2021-09-22 | 2023-03-30 | Sage Therapeutics, Inc. | Deuterated positive nmda-modulating compounds and methods of use thereof |
WO2023114224A1 (en) | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
CN115624555A (zh) * | 2022-02-24 | 2023-01-20 | 中国药科大学 | 猪去氧胆酸在制备抗抑郁药物中的应用 |
WO2024112759A1 (en) * | 2022-11-21 | 2024-05-30 | Sage Therapeutics, Inc. | Negative nmda-modulating compounds and methods of use thereof |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2594323A (en) * | 1948-07-22 | 1952-04-29 | Upjohn Co | 24-substituted delta 5-cholene-3, 24-diols |
US3079385A (en) * | 1961-01-24 | 1963-02-26 | Roussel Uclaf | Novel process of preparation of polyhydroxylated pregnanes |
US3206459A (en) | 1962-10-19 | 1965-09-14 | Syntex Corp | 10alpha-pregnan-19-ol derivatives |
US4071625A (en) | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
EP0701444B1 (en) | 1993-05-24 | 2010-04-07 | Purdue Pharma Ltd. | Methods and compositions for inducing sleep |
IL110309A0 (en) | 1993-07-15 | 1994-10-21 | Univ Kentucky Res Found | A method of protecting against neuron loss |
DK0752860T3 (da) | 1994-02-14 | 2000-11-13 | Euro Celtique Sa | Androstaner og pregnaner til allosterisk modulering af GABA-receptor |
US5595996A (en) | 1994-10-25 | 1997-01-21 | Merck & Co., Inc. | 7-substituted 4-aza cholanic acid derivatives and their use |
WO1996016076A1 (en) * | 1994-11-23 | 1996-05-30 | Cocensys, Inc. | Androstane and pregnane series for allosteric modulation of gaba receptor |
JPH08268917A (ja) * | 1995-03-31 | 1996-10-15 | D D S Kenkyusho:Kk | 癌組織への移行性の高い制癌剤 |
HUP9901138A3 (en) | 1995-06-06 | 1999-11-29 | Cocensys Inc Irvine | Neuroactive steroids of the androstane and pregnane series |
CZ408097A3 (cs) | 1995-06-23 | 1998-06-17 | Novo Nordisk A/S | Sloučeniny regulující meiosu |
US6645953B2 (en) | 1995-06-23 | 2003-11-11 | Novo Nordisk A/S | Meiosis regulating compounds |
JP4313435B2 (ja) * | 1995-07-24 | 2009-08-12 | トラスティーズ オブ ボストン ユニバーシティー | プレグネノロンサルフェート誘導体によるnmdaレセプター活性の抑制 |
US5888996A (en) | 1995-07-26 | 1999-03-30 | Trustees Of Boston University | Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity |
WO1998005337A1 (en) * | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
US6122371A (en) | 1997-07-22 | 2000-09-19 | Atwell; Ronald C. | Apparatus for protecting coin-operated telephones from vandalism and larceny |
IL139241A0 (en) | 1998-05-13 | 2001-11-25 | Novo Nordisk As | Meiosis regulating compounds |
US8541600B2 (en) | 1998-11-24 | 2013-09-24 | Harbor Therapeutics, Inc. | 11-aza, 11-thia and 11-oxa sterol compounds and compositions |
GB9910934D0 (en) | 1999-05-11 | 1999-07-14 | Res Inst Medicine Chem | Chemical compounds |
GB0000228D0 (en) | 2000-01-06 | 2000-03-01 | Phytopharm Plc | Fluoro substituted sapogenins and their use |
GB0019290D0 (en) | 2000-08-04 | 2000-09-27 | Symphar Sa | Methods for inducing apolipoprotein E secretion |
GR1003861B (el) | 2000-12-29 | 2002-04-11 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
GB0107822D0 (en) | 2001-03-28 | 2001-05-23 | Phytopharm Plc | Sapogenin derivatives their synthesis and use methods based upon their use |
US20070197484A1 (en) | 2001-05-03 | 2007-08-23 | Ching Song | Method of treating disorder related to high cholesterol concentration |
TW200300078A (en) | 2001-11-08 | 2003-05-16 | Univ Chicago | Method of treating disorder related to high cholesterol concentration |
WO2003049685A2 (en) | 2001-12-07 | 2003-06-19 | The Regents Of The University Of California | Treatment for age-related macular degeneration |
KR20100093621A (ko) | 2002-03-27 | 2010-08-25 | 파이토팜 피엘씨 | 사포게닌 및 그 유도체의 치료 방법 및 용도 |
CN102727501A (zh) | 2002-03-27 | 2012-10-17 | 菲特法姆股份有限公司 | 皂角苷配基及其衍生物的用途 |
WO2004055201A2 (en) | 2002-12-13 | 2004-07-01 | Bayer Healthcare Ag | Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease |
FR2850023B1 (fr) * | 2003-01-17 | 2007-04-06 | Mapreg | Medicaments pour le systeme nerveux |
GB0403889D0 (en) | 2004-02-21 | 2004-03-24 | Univ Edinburgh | Uses of er-beta modulators |
WO2006037016A2 (en) | 2004-09-27 | 2006-04-06 | The Regents Of The University Of California | Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury |
JP2009528291A (ja) | 2006-02-27 | 2009-08-06 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | オキシステロール化合物及びヘッジホッグ経路 |
JP5130591B2 (ja) * | 2006-04-22 | 2013-01-30 | ハーバー セラピューティクス, インコーポレイテッド | 薬物および用途 |
GB0619860D0 (en) * | 2006-10-06 | 2006-11-15 | Birkeland Innovasjon As | Treatment of insulin resistance and disorders associated therewith |
WO2008057468A1 (en) | 2006-11-02 | 2008-05-15 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
WO2008157786A1 (en) | 2007-06-20 | 2008-12-24 | Auspex Pharmaceutical, Inc. | Substituted n-aryl pyridinones as fibrotic inhibitors |
GB0712494D0 (en) | 2007-06-27 | 2007-08-08 | Isis Innovation | Substrate reduction therapy |
WO2009059239A2 (en) * | 2007-11-02 | 2009-05-07 | Mayo Foundation For Medical Education And Research | REDUCING Aβ42 LEVELS AND Aβ AGGREGATION |
US20110118353A1 (en) | 2007-11-06 | 2011-05-19 | N. V. Organon | Method of hormone suppression in humans |
WO2009090063A1 (en) | 2008-01-16 | 2009-07-23 | Jado Technologies Gmbh | Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases |
BRPI0912362A2 (pt) | 2008-05-09 | 2015-10-06 | Univ Emory | antagonista do receptor nmda para o tratamento de transtornos neuropsiquiátricos |
WO2010065709A2 (en) | 2008-12-03 | 2010-06-10 | Amin Khan | Hydroxamic acid derivatives, preparation and therapeutic uses thereof |
WO2010075282A1 (en) | 2008-12-22 | 2010-07-01 | University Of Washington | Molecular inhibitors of the wnt/beta-catenin pathway |
WO2010088408A2 (en) | 2009-01-28 | 2010-08-05 | Emory University | Subunit selective nmda receptor antagonists for the treatment of neurological conditions |
EP2459581A4 (en) | 2009-07-29 | 2012-12-26 | Univ Chicago | LIVER X RECEPTOR AGONISTS |
WO2011028794A2 (en) | 2009-09-01 | 2011-03-10 | Lazarus Therapeutics, Inc. | Treatment of huntington's disease with cycloserine and an nmda receptor antagonist |
FR2953138B1 (fr) | 2009-12-02 | 2015-10-16 | Assist Publ Hopitaux Marseille | Composes aminosteroidiens pour une application topique locale pour la decolonisation cutaneo-muqueuse de staphylococcus aureus |
KR101692275B1 (ko) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | 2차 구조 안정화된 nmda 수용체 조절제 및 그의 용도 |
US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
US20120035156A1 (en) | 2010-08-09 | 2012-02-09 | Daniela Alberati | Combination of glyt1 compound with antipsychotics |
US8969525B2 (en) | 2010-11-09 | 2015-03-03 | Enzo Life Sciences, Inc. | Hydroxycholesterol immunoassay |
US20150031655A1 (en) | 2011-04-15 | 2015-01-29 | University Of North Dakota | Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases |
US20140335050A1 (en) | 2011-05-27 | 2014-11-13 | The General Hospital Corporation | Methods, compositions, and kits for the treatment of cancer |
JP2014521662A (ja) | 2011-07-29 | 2014-08-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | GABAA受容体のモジュレーターとしての新規な17β−ヘテロアリール置換ステロイド |
US20150158903A1 (en) | 2011-09-08 | 2015-06-11 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
CN108976272B (zh) | 2011-10-14 | 2021-05-25 | 萨奇治疗股份有限公司 | 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途 |
EP2841067A4 (en) | 2012-04-25 | 2016-04-13 | Univ California | MEDICINAL SCREENING PLATFORM FOR THE RETT SYNDROME |
WO2014028942A2 (en) | 2012-08-17 | 2014-02-20 | Trueex Group Llc | Interoffice bank offered rate financial product and implementation |
SI2935307T1 (en) | 2012-12-18 | 2018-08-31 | Washington University | Non-reactive 19-alkoxy-17-substituted steroids useful in therapeutic procedures |
WO2014115167A2 (en) | 2013-01-23 | 2014-07-31 | Sphaera Pharma Pvt. Ltd. | Novel compounds of 11beta-hydroxy-steroids for use in mitochondria biogenesis and diseases associated with mitochondrial dysfunction or depletion |
SG11201505934XA (en) | 2013-01-29 | 2015-09-29 | Naurex Inc | Spiro-lactam nmda receptor modulators and uses thereof |
BR112015022174B1 (pt) | 2013-03-13 | 2022-07-05 | Sage Therapeutics, Inc | Compostos esteróides neuroativos, sua composição farmacêutica e seu uso |
EP3865135A3 (en) | 2013-03-13 | 2021-11-03 | Sage Therapeutics, Inc. | Neuroactive steroids for use in therapy |
EP4306114A1 (en) | 2014-06-18 | 2024-01-17 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
EP3166613A4 (en) | 2014-07-09 | 2018-02-21 | Duke University | Compositions and methods for the repair of myelin |
SG10202011773UA (en) | 2014-10-07 | 2021-01-28 | Sage Therapeutics Inc | Neuroactive compounds and methods of use thereof |
EP4316591A3 (en) | 2015-07-06 | 2024-04-24 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
DK3319611T3 (da) | 2015-07-06 | 2021-04-12 | Sage Therapeutics Inc | Oxysteroler og fremgangsmåder til anvendelse deraf |
DK3319612T3 (da) | 2015-07-06 | 2021-08-23 | Sage Therapeutics Inc | Oxysteroler og fremgansmåder til anvendelse derfor |
GB2557875A (en) | 2015-09-02 | 2018-07-04 | Univ Swansea | Diagnostic methods and kits |
CA3055653A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Lipid nanoparticle formulation |
WO2018237350A1 (en) | 2017-06-23 | 2018-12-27 | Intercept Pharmaceuticals, Inc. | METHODS AND INTERMEDIATES FOR PREPARING BILARY ACID DERIVATIVES |
EA202091144A1 (ru) | 2017-11-10 | 2020-09-16 | Маринус Фармасьютикалз, Инк. | Ганаксолон для использования в лечении наследственных эпилептических заболеваний |
-
2012
- 2012-09-07 US US14/343,603 patent/US20150158903A1/en not_active Abandoned
- 2012-09-07 PT PT127667665T patent/PT2753632T/pt unknown
- 2012-09-07 WO PCT/US2012/054261 patent/WO2013036835A1/en active Application Filing
- 2012-09-07 HU HUE12766766A patent/HUE062616T2/hu unknown
- 2012-09-07 CN CN201711063812.0A patent/CN107936076B/zh active Active
- 2012-09-07 JP JP2014529913A patent/JP6205362B2/ja active Active
- 2012-09-07 PL PL12766766.5T patent/PL2753632T3/pl unknown
- 2012-09-07 BR BR112014005373-1A patent/BR112014005373B1/pt active IP Right Grant
- 2012-09-07 HR HRP20230747TT patent/HRP20230747T1/hr unknown
- 2012-09-07 RU RU2014113548A patent/RU2665571C2/ru active
- 2012-09-07 DK DK12766766.5T patent/DK2753632T3/da active
- 2012-09-07 EP EP23171488.2A patent/EP4245369A3/en active Pending
- 2012-09-07 FI FIEP12766766.5T patent/FI2753632T3/fi active
- 2012-09-07 CA CA2848212A patent/CA2848212C/en active Active
- 2012-09-07 AU AU2012304412A patent/AU2012304412A1/en not_active Abandoned
- 2012-09-07 CN CN201280054927.2A patent/CN103958540B/zh active Active
- 2012-09-07 LT LTEPPCT/US2012/054261T patent/LT2753632T/lt unknown
- 2012-09-07 ES ES12766766T patent/ES2951664T3/es active Active
- 2012-09-07 SI SI201232034T patent/SI2753632T1/sl unknown
- 2012-09-07 EP EP12766766.5A patent/EP2753632B1/en active Active
- 2012-09-07 CN CN202111105989.9A patent/CN113956315A/zh active Pending
- 2012-09-07 RS RS20230525A patent/RS64332B1/sr unknown
-
2015
- 2015-01-15 HK HK15100472.0A patent/HK1200173A1/xx unknown
-
2017
- 2017-06-29 AU AU2017204452A patent/AU2017204452B2/en active Active
- 2017-09-04 JP JP2017169737A patent/JP2018021059A/ja not_active Withdrawn
-
2018
- 2018-08-28 US US16/114,791 patent/US10759828B2/en active Active
-
2019
- 2019-01-25 JP JP2019011169A patent/JP6777773B2/ja active Active
- 2019-09-10 AU AU2019227507A patent/AU2019227507B2/en active Active
-
2020
- 2020-07-29 US US16/942,235 patent/US20210147470A1/en not_active Abandoned
- 2020-10-08 JP JP2020170611A patent/JP2021008504A/ja not_active Withdrawn
-
2021
- 2021-06-21 AU AU2021204183A patent/AU2021204183B2/en active Active
-
2022
- 2022-03-29 US US17/707,303 patent/US20230192756A1/en active Pending
-
2023
- 2023-01-10 JP JP2023001738A patent/JP2023040180A/ja active Pending
- 2023-05-15 AU AU2023203028A patent/AU2023203028A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20230747T1 (hr) | Neuroaktivni steroidi, pripravci i njihova uporaba | |
HRP20201126T1 (hr) | Neuroaktivni steroidi, njihovi pripravci i uporabe | |
DOP2009000148A (es) | Derivados de ester y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides | |
IN2014MN01839A (hr) | ||
SA518391477B1 (ar) | أملاح فالبينازين وصور متعددة الشكل البلوري منها | |
RU2014145682A (ru) | Органические соединения | |
BR112014028715A2 (pt) | banho de chapeamento para deposição sem eletrodo de camadas de níquel | |
MX2012012225A (es) | Profármacos de agentes tearapéuticos de liberación de óxido nítrico. | |
BR112013027670A2 (pt) | "composto de amida, composição farmacêutica e medicamento que o compreende e antagonista de rory" | |
WO2012116290A3 (en) | Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same | |
HRP20171587T1 (hr) | Spojevi, pripravci i postupci pogodni za mobilizaciju kolesterola | |
BR112015009395A2 (pt) | processo para preparação de derivados do ácido biliar | |
UY32571A (es) | Compuestos derivados de pirazol amida | |
JP2018519329A5 (hr) | ||
UY31208A1 (es) | Acidos fenoxiacéticos y sales y solvatos de los mismos utiles como compuestos farmacéuticos para el tratamiento de trastornos respiratorios, composiciones farmacéuticas que los contienen y procedimientos para la preparacion de los mismos. | |
AR059963A1 (es) | Derivados de amina | |
BR112015004529A8 (pt) | alcóxi pirazóis, seu uso como ativadores de guanilato ciclase solúvel e composição farmacêutica que os compreende | |
AR065622A1 (es) | Derivados de 3-ciano -4- (4-fenil- piperidin -1- il) piridin -2- ona | |
CU24037B1 (es) | Dicianopiridinas alquilamino-sustituidas y sus profármacos de éster de aminoácido | |
AR081154A1 (es) | Compuestos de amino-oxazinas y amino-dihidrotiazina como moduladores de beta-secretasa y metodos de uso | |
AR070907A1 (es) | Formas cristalinas de derivado de nitrocatecol | |
HRP20210793T1 (hr) | Derivati kromana, izokromana i dihidroizobenzofurana kao mglur2-negativni alosterni modulatori, pripravci i njihova uporaba | |
IN2014DN00090A (hr) | ||
AR075626A1 (es) | Metodos para administrar (4ar,10ar)-1-n- propil-1,2,3,4,4a,5,10,10a- octahidro -benzo (g) quinolin-6,7-diol y sus composiciones farmaceuticas. uso. | |
BR112014004732A2 (pt) | composto benzotiazolona |